As Mental Health Awareness Week 2019 begins (13/5/19), King’s College London Professor of Psychiatry Allan Young offers his thoughts on how a new European pharmacovigilance consortium could pave the way for new mental health drugs for UK patients.
Dr Simon Hendricks, clinical strategy lead at FDB (First Databank), is excited by the recent attention from Whitehall to improving NHS prescribing. He asks what progress is already being made, what needs to happen next, and where technology can play a role.
The rise of digital therapeutics and the shift of the health market towards payment for outcomes could be seen as a significant double threat to pharma. However, cross-industry collaboration could turn these threats into opportunities, says S3 Connected Health's Jim O’Donoghue.
Compliance training should focus on promoting trust and integrity, rather than on fear of the consequences of non-compliance. Louise Vamvoukaki offers an insight into how AstraZeneca is working to ensure that its globally dispersed workforce are all living and breathing the same values and ethics.